Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)

Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y) Publisher Pubmed

Izadi S^{1, 2} ; Moslehi A¹ ; Kheiry H³ ; Kiani FK¹ ; Ahmadi A⁴ ; Masjedi A⁵ ; Ghani S⁶ ; Rafiee B⁷ ; Karpisheh V¹ ; Hajizadeh F¹ ; Atyabi F⁸ ; Assali A⁸ ; Tekie FSM⁹ ; Namdar A¹⁰ Show All Authors

Izadi S^{1, 2}
Moslehi A¹
Kheiry H³
Kiani FK¹
Ahmadi A⁴
Masjedi A⁵
Ghani S⁶
Rafiee B⁷
Karpisheh V¹
Hajizadeh F¹
Atyabi F⁸
Assali A⁸
Tekie FSM⁹
Namdar A¹⁰
Ghalamfarsa G¹¹
Sojoodi M¹²
Jadidiniaragh F^{1, 13}

Show Affiliations

1. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3. Division of Genetics, Department of Biology, Faculty of Science, University of Isfahan, Isfahan, Iran
4. Department of Chemical and Materials Engineering, The University of Alabama in Huntsville, Huntsville, 35899, AL, United States
5. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6. Student Research Committee, Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7. Department of Biology, Faculty of Basic Science, Payame Noor University, Tehran, Iran
8. Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
9. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
10. Department of Oncology, Cross Cancer Institute, The University of Alberta, Edmonton, AB, Canada
11. Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
12. Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and, Harvard Medical School, Boston, United States
13. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Pharmaceutical Research Published:2022

Abstract

The Editor-in-Chief has retracted this article because of similarities between figures within this article, as well as between figures in this article and previously published work [1]. In particular: • Figure 4C (panel CT-26 GAPDH) has similarities with Figure 4C (panel 4T1 GAPDH). • Figure 6a (panel untreated vs 4T1) has similarities with Figure 6a (panel NP. Vs 4T1) of [1]. • Figure 6a (panel Untreated vs B16-F10) has similarities with Figure 6a (panel NP. Vs B16-F10) of [1]. • Figure 6a (panel NP-siRNA HIF-1α vs CT26) has similarities with Figure 6a (panel NP-siRNA CD73 vs CT26) of [1]. • Figure 6a (panel NP-siRNA HIF-1α – Dinaciclib vs 4T1) has similarities with Figure 6a (panel NP-siRNA CD73/ HIF-1α vs CT26) of [1]. • Figure 7a (panel Untreated vs 4T1) has similarities with Figure 7a (panel NP-siRNA HIF-1α vs 4T1) of [1]. • Figure 7a (panel Untreated vs B16-F10) has similarities with Figure 7a (panel Untreated vs 4T1) of [1]. • Figure 7a (panel Untreated vs CT26) has similarities with Figure 7a (panel NP-siRNA HIF-1α vs B16F10) of [1]. The authors Farhad Jadidi-Niaragh, Sepideh Ghani, Afshin Namdar, Farnaz Hajizadeh, Ghasem Ghalamfarsa, Vahid Karpisheh, Mozhdeh Sojoodi and Armin Ahmadi agree to this retraction. The authors Sepideh Izadi, Farnaz Sadat Mirzazadeh Tekie and Akram Assali do not agree to this retraction. The authors Ali Masjedi and Asma Moslehi have not explicitly stated whether they agree or disagree with this retraction. The authors Fariba Karoon Kiani, Behnam Rafiee and Fatemeh Atyabi have not responded to any correspondence from the editor about this retraction. The editor was not able to obtain a current email address for author Hadiseh Kheyri. 1. Hajizadeh F, Ardebili SM, Moornani MB, Masjedi A, Atyabi F, Kiani M, Namdar A, Karpisheh V, Izadi S, Baradaran B, Azizi G. Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. European journal of pharmacology. 2020 Sep 5;882:173,235. © Springer Science+Business Media, LLC, part of Springer Nature 2022.

Style	Citing Format
MLA	Izadi S, et al.. "Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)." Pharmaceutical Research, vol. 39, no. 12, 2022, pp. 3383-3384.
APA	Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, Ghani S, Rafiee B, Karpisheh V, Hajizadeh F, Atyabi F, Assali A, Tekie FSM, Namdar A, Ghalamfarsa G, Sojoodi M, Jadidiniaragh F (2022). Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y). Pharmaceutical Research, 39(12), 3383-3384.
Chicago	Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, Ghani S, et al.. "Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)." Pharmaceutical Research 39, no. 12 (2022): 3383-3384.
Harvard	Izadi S et al. (2022) 'Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)', Pharmaceutical Research, 39(12), pp. 3383-3384.
Vancouver	Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, et al.. Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y). Pharmaceutical Research. 2022;39(12):3383-3384.
BibTex	@article{ author = {Izadi S and Moslehi A and Kheiry H and Kiani FK and Ahmadi A and Masjedi A and Ghani S and Rafiee B and Karpisheh V and Hajizadeh F and Atyabi F and Assali A and Tekie FSM and Namdar A and Ghalamfarsa G and Sojoodi M and Jadidiniaragh F}, title = {Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)}, journal = {Pharmaceutical Research}, volume = {39}, number = {12}, pages = {3383-3384}, year = {2022} }
RIS	TY - JOUR AU - Izadi S AU - Moslehi A AU - Kheiry H AU - Kiani FK AU - Ahmadi A AU - Masjedi A AU - Ghani S AU - Rafiee B AU - Karpisheh V AU - Hajizadeh F AU - Atyabi F AU - Assali A AU - Tekie FSM AU - Namdar A AU - Ghalamfarsa G AU - Sojoodi M AU - Jadidiniaragh F TI - Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y) JO - Pharmaceutical Research VL - 39 IS - 12 SP - 3383 EP - 3384 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract